Erye Pharmaceutical Co. Ltd of Suzhou tightened its relationship with NeoStem, Inc. (NYSE Alternext: NBS) when principals of Eyre invested $500,000 in a private market financing of NeoStem. The investors paid $1.25 per unit; each unit includes one share of NeoStem and one warrant to purchase an additional share at $1.75. NeoStem ended the trading session at $.91, lower by one cent. In November, NeoStem agreed to acquire a 51% stake in Eyre Pharma. More details...

Stock Symbol: (OTCBB: CHBP)